Literature DB >> 762081

Immunological characterization of multiple weight forms of human cell plasminogen activators.

D Vetterlein, P L Young, T E Bell, R Roblin.   

Abstract

Several molecular weight forms of plasminogen activator (PA) activity have been observed in serum-free conditioned media from human cells in culture. An antibody inhibition technique is described which combines inhibition of enzyme activity by anti-urokinase IgG with sodium dodecyl sulfate-gel electrophoresis to determine whether different molecular weight forms of human cell PA's are immunologically related to urokinase. Plasminogen activator forms with molecular weights of 85,000 to 95,000, 50,000 to 60,000, and 36,000 were inhibited by anti-urokinase IgG. In contrast, PA forms with molecular weights in the 73,000 range from three different types of human cells were not inhibited by comparable concentrations of the antibody. Human embryonic kidney cultures contain only anti-urokinase IgG-inhibitable PA forms, while melanoma-derived Malme-3M cultures contain only anti-urokinase IgG-resistant forms. Cultures of tumorigenic Detroit 562 cells and nontumorigenic IMR-90 cells contain a mixture of "antibody-sensitive" and "antibody-resistant" PA forms. The antibody-resistant 73,000-dalton PA form may be a precursor of the smaller antibody-sensitive, urokinase-related forms, or it may be the product of a second plasminogen activator gene which codes for a protein immunologically and structurally different from urokinase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762081

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 2.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 3.  Tumor invasion and host extracellular matrix.

Authors:  B U Pauli; D E Schwartz; E J Thonar; K E Kuettner
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

4.  Effect of the extracellular matrix on plasminogen activator isozyme activities of human mammary epithelial cells in culture.

Authors:  N S Yang; C Park; C Longley; P Furmanski
Journal:  Mol Cell Biol       Date:  1983-06       Impact factor: 4.272

5.  Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation.

Authors:  H A Chapman; O L Stone; Z Vavrin
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

6.  Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.

Authors:  A Kjaeldgaard; B Larsson; B Astedt
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

7.  Immunological characterisation of plasminogen activators in the human vessel wall.

Authors:  H Ljungnér; L Holmberg; A Kjeldgaard; I M Nilsson; B Astedt
Journal:  J Clin Pathol       Date:  1983-09       Impact factor: 3.411

Review 8.  Extracellular matrix destruction by invasive tumor cells.

Authors:  P A Jones; Y A De Clerck
Journal:  Cancer Metastasis Rev       Date:  1982       Impact factor: 9.264

9.  Prognostic role of urokinase-type plasminogen activator in human gliomas.

Authors:  D W Hsu; J T Efird; E T Hedley-Whyte
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

10.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.